Amphastar Pharmaceuticals Return on Equity

Amphastar Pharmaceuticals (AMPH) currently reports a ROE of 10.24%. That is below the Healthcare sector average of 29.03%. Use the charts on this page to explore Amphastar Pharmaceuticals's ROE history and peer comparisons.

Amphastar Pharmaceuticals's ROE of 10.24% is lower than the Healthcare sector average of 29.03%. That is roughly 64.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Amphastar Pharmaceuticals's current 10.24% should be judged against Healthcare norms (sector average: 29.03%) and against AMPH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 10.24%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.03%. From there, open related valuation or income-statement pages for Amphastar Pharmaceuticals, and consider following AMPH for alerts when major investors trade the stock.

Amphastar Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows 10.24% versus a sector average near 29.03%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AMPH with unrelated industries.